Are you sure you want to leave?
In stage 3 to 5 non-dialysis chronic kidney disease (ND-CKD) patients, Kidney Disease: Improving Global Outcomes (KDIGO) recommends the following.
No recommendation for FGF-23 to be measured in clinical practice.
Adapted from KDIGO 2017.1
Opportunities to treat abnormalities related to CKD–MBD and potentially avoid the development of bone and cardiovascular complications are often missed due to poor levels of adherence to KDIGO’s monitoring guidelines.2
According to KDIGO, due to the risk of hypercalcaemia, active vitamin D (AVD) and AVD analogues should be reserved for patients with stage 4 to 5 CKD and severe and progressive hyperparathyroidism.1
Whilst KDIGO suggests that nutritional vitamin D (NVD) should be used to address vitamin D deficiency and insufficiency in ND-CKD, it also acknowledges that no studies of sufficient duration are available, and thus the therapy remains unproven in patients with stage 3 to 4 CKD.1
*2C = A suggestion rather than a recommendation (2), with low quality of evidence (C).1
25(OH)D: 25-hydroxyvitamin D; AVD: active vitamin D; Ca: calcium; CKD: chronic kidney disease; CKD–MBD: chronic kidney disease–mineral and bone disorder; FGF-23: fibroblast growth factor-23; KDIGO: Kidney Disease–Improving Global Outcomes; ND-CKD: non-dialysis chronic kidney disease; PO: phosphate; PTH: parathyroid hormone; RRT: renal replacement therapy; SHPT: secondary hyperparathyroidism.
You are viewing a website from Vifor Pharma. This material is only intended for healthcare professionals (“HCPs”) from Europe. If you are not the intended audience, please leave this website. By checking the box, you acknowledge that you are a HCP from Europe. Approval conditions for products may vary from country to country. Before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.